Angiogene, EntreMed Inc. (ENMD) deal

ENMD's majority-owned subsidiary MaxCyte Inc. partnered with Angiogene to research and develop a non-viral therapy to treat congestive heart failure (CHF) caused by myocardial infarction. Angiogene w...